119 related articles for article (PubMed ID: 35170328)
1. Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.
Diz-Lois Palomares MªT; Porta Sánchez Á; Elberdin Pazos L; González Conde B; Outeda Macías M; Vázquez Rey MT; Estévez Prieto E; Martín Herranz I; Alonso Aguirre P
Rev Esp Enferm Dig; 2022 Dec; 114(12):708-712. PubMed ID: 35170328
[TBL] [Abstract][Full Text] [Related]
2. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
[TBL] [Abstract][Full Text] [Related]
3. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
5. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
[TBL] [Abstract][Full Text] [Related]
7. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
[TBL] [Abstract][Full Text] [Related]
8. Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.
Calvo Moya M; González Lama Y; Ruíz Antorán B; Omella Usieto I; El Hajra Martinez I; Santos Pérez E; Menchén Viso B; Matallana Royo V; González Partida I; de Lucas Tellez de Meneses R; Bella Castillo P; González Rodriguez M; Vera Mendoza MI
Crohns Colitis 360; 2023 Jan; 5(1):otac051. PubMed ID: 36785555
[TBL] [Abstract][Full Text] [Related]
9. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
Billioud V; Sandborn WJ; Peyrin-Biroulet L
Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
11. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study.
Pouillon L; Lamoureux A; Pineton de Chambrun G; Vuitton L; Pariente B; Zallot C; Dufour G; Fumery M; Baumann C; Amiot A; Nancey S; Rousseau H; Peyrin-Biroulet L
Dig Liver Dis; 2019 Feb; 51(2):236-241. PubMed ID: 30502230
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
[TBL] [Abstract][Full Text] [Related]
13. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
14. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
Roblin X; Genin C; Nancey S; Williet N; Veyrard P; Boschetti G; Phelip JM; Berger AE; Killian M; Waeckel L; Flourie B; Paul S
Inflamm Bowel Dis; 2022 May; 28(5):720-727. PubMed ID: 34405867
[TBL] [Abstract][Full Text] [Related]
15. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
16. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
18. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
[TBL] [Abstract][Full Text] [Related]
20. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.
Taxonera C; Martínez-Montiel MP; Barreiro-de-Acosta M; Vera I; Lorente R; Vega P; Diz-Lois MT; Fuentes Coronel AM; Pérez Calle JL; Casis B; Ferreiro-Iglesias R; Calvo M; Olivares D; Alba C
Therap Adv Gastroenterol; 2021; 14():17562848211056157. PubMed ID: 35116079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
